Trial
NCT04982289
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Generalized Myasthenia Gravis
Intervention
ALXN1830
Why stopped
Sponsor decision to terminate program
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-11